Blog

National Center for Civil and Human Rights Unveils Broken Promises Gallery “Guided” by Ida B. Wells

ATLANTA, GEORGIA / ACCESS Newswire / December 5, 2025 / The National Center for Civil and Human Rights’ new gallery, “Broken Promises,” is a permanent exhibit on Reconstruction-the period after the Civil War and Emancipation when America first attempted to build a multi-racial democracy. The Center invites people to experience the new gallery which opens to the public today, December 5, 2025, as part of the Center’s $58 million expansion.

The gallery presents Black progress during the Reconstruction Era, when nearly four million newly freed Black Americans claimed their rights as citizens, voted, won elected office, created schools, and reshaped economic and civic life across the South. It also presents the violent backlash that met and then suppressed those gains – through racial terror, political disenfranchisement, and Jim Crow legal segregation.

“Reconstruction reminds us that the expansion of rights in America has never moved in a straight line. Every reform toward wider freedom has been accompanied by efforts to limit those rights,” said Jill Savitt, the CEO of the Center. “Recognizing that pattern helps us understand the forces that have long shaped America, up until today.”

Curated by the Center’s Chief Program Officer, Kama Pierce, the gallery has anti-lynching crusader Ida B. Wells as its “docent,” and focuses on three cities – Wilmington, N.C., Atlanta, Ga., and Tulsa, Okla. In each city, Black achievement provoked white backlash that resulted in massacres and racial terror.

The immersive gallery contains artifacts from the Without Sanctuary Collection, including a fragment of a noose and photographs of lynchings that were turned into postcards for entertainment. The artifacts deepen visitors’ understanding of how racial terror was wielded as a strategy.

The gallery’s memorial space features a historical marker honoring Mary Turner, who was lynched in 1918. Turner’s family erected the public marker to honor her – but it was consistently defaced. The family donated the marker — marred by 11 bullet holes — to the Center. Artist Lonnie Holley has interpreted the marker in the gallery’s memorial space.

“The Mary Turner marker is a powerful artifact that bears witness twice – first to the original terror, and again to the present resistance to let the truth be told,” said Pierce.

The Center decided to add a gallery on Reconstruction because the era has not always been fully or accurately represented in American classrooms. The Center also wanted to provide more context for its signature gallery on the Civil Rights Movement.

“After Reconstruction, the United States entered a decades-long period of Jim Crow segregation and unequal protection for Black Americans,” said Pierce. “The Civil Rights Movement emerged not as a new struggle, but as a renewed demand to enforce the promises first made during Reconstruction.”

The Center received a $2 million grant from the Mellon Foundation for the exhibition.

About the National Center for Civil and Human Rights
The National Center for Civil and Human Rights is a museum and cultural organization that inspires the changemaker in each of us. Opened in 2014, the Center connects US civil rights history to global human rights movements today. Our experiences highlight people who have worked to protect rights and who model how individuals create positive change. For more information, visit civilandhumanrights.org. Follow us on Facebook, Twitter, Instagram @civilandhumanrights and LinkedIn at linkedin.com/company/ncchr.

###

Contact Information
Tenisha Griggs
Head of Marketing
tgriggs@civilandhumanrights.org
404-973-7710

SOURCE: National Center for Civil and Human Rights

View the original press release on ACCESS Newswire

ESTERO, FL / ACCESS Newswire / December 4, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, today provides a business update for the quarter ended September 30, 2025.

Q3 2025 and Recent Highlights

• Expanded its scientific team with the addition of Mark J. Jaroszeski, PhD, a tenured professor in the Department of Medical Engineering at the University of South Florida. Dr. Jaroszeski, who holds a PhD in Engineering Science with a dissertation focused on mechanically facilitated cell-cell electrofusion. His expertise is expected to assist in further developing Aspire’s unique sublingual delivery technology.

• Submitted its Pre-IND meeting request and briefing package to the U.S. Food and Drug Administration (FDA). The submission concerns the Company’s lead product candidate, a fast-acting, high-dose sublingual aspirin formulation for the treatment of suspected acute myocardial infarction (AMI) and represents a significant milestone on the path to potential FDA approval. On November 13, 2025, the FDA responded positively to the request and stated it would provide written responses in lieu of a meeting no later than January 2, 2026.

• Participated in the CPHI Frankfurt trade show, the world’s largest pharmaceutical event. The Company engaged in numerous strategic discussions with global pharmaceutical companies regarding technical collaboration and licensing opportunities for its lead product candidate, a novel sublingual high-dose aspirin. The conference has led to several licensing opportunities that the Company is considering.

• Filed an omnibus patent application with the U.S. Patent and Trademark Office for its sublingual delivery technology. This application – which seeks patent protection of Aspire’s proprietary technology in a variety of classes of drugs and other substances–focuses exclusively on protecting the Company’s advanced sublingual drug delivery system, which is designed to enhance the pharmacokinetic performance of Active Pharmaceutical Ingredients (“APIs”) and other substances into the bloodstream, increasing bioavailability and improving speed of onset. The omnibus patent supplements the patent protections already provided by Aspire’s previously filed patents.

• Shared its pipeline progress and key milestones expected through the remainder of 2025 and early 2026. The company is focusing its pipeline on reformulating approved drugs for multi-billion-dollar markets by utilizing its disruptive, patent-pending sublingual delivery technology and anticipates filing as many as five to ten additional patents before the end of Q1 2026.

• Began its influencer marketing campaign designed to drive conversion, brand awareness and loyalty for its innovative BUZZ BOMB™ caffeine product. Featuring 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), BUZZ BOMB™ provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken as needed for immediate effect.

• Increased the production capacity of its BUZZ BOMB™ single dose caffeine supplement through a new manufacturing relationship with SupraNaturals, a well-established contract manufacturer of nutritional and dietary supplements. As part of this agreement, Aspire Biopharma announced an initial production order of two million servings (100,000 20-packs) of BUZZ BOMB™ caffeine supplement, marking a significant milestone in the Company’s expansion efforts. The new product will be available for sale just before Christmas.

• Published positive final data from its randomized, crossover bioavailability trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Aspire’s investigational new sublingual aspirin product compared to chewed uncoated aspirin tablets in healthy adults. The sublingual formulation begins to inhibit platelet aggregation in under two minutes, acting approximately four to five times as fast as chewed aspirin.

• Announced the successful launch and distribution of over 30,000 BUZZ BOMB™ sample four-packs, its new sublingual caffeine supplement, at FitCon and FitExpo, held August 1-3, in Salt Lake City and Anaheim, with an estimated combined attendance in excess of 70,000 people.

• Announced that the Company’s Board of Directors (Board) has appointed Kraig Higginson as interim Chief Executive Officer (CEO), effective July 24, 2025. Mr. Higginson serves as Chairman of the Board and previously served as CEO of Aspire for nearly four years.

• Buzz Bomb Caffeine Company LC, a wholly owned subsidiary of Aspire:

  • Unveiled its new e-commerce solution, buzzbombcaffeine.com with BUZZ BOMB™ as its featured launch product. This new seamless direct-to-consumer shopping experience allows consumers to order BUZZ BOMB™ on the Buzz Bomb platform and have them shipped directly to their door with access to exclusive promotions, and customer support. To celebrate the launch, customers who register for Buzz Bomb’s e-commerce site will have first access to special pricing, free shipping offers, and other promotions. The site features an introductory sample pack of four flavors as well as 30-packs in various flavors.

  • Announced positive initial consumer feedback from the Company’s sampling of its sublingual caffeine supplement, BUZZ BOMB™. featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar caffeine market to help athletes, fitness enthusiasts, and others wanting a lift to maximize their performance potential. Buzz Bomb™ provides nearly instant energy, in easy-to-use convenient packs, which can be taken easily and without the need for mixing with water or relying on unhealthy energy drinks or soda.

Anticipated Upcoming Milestones

• Sublingual High-dose Aspirin (Lead Program)

  • H1 2026: Target submission of New Drug Application (NDA).

• Sublingual ED medication

  • H1 2026: Finalize formulation and manufacture test product.

  • Mid-2026: Initiate Phase 1 pharmacokinetic (PK) clinical cross-over study.

Kraig Higginson, Interim CEO of Aspire Biopharma, commented:

“Our third-quarter results represent the blueprint for our future value creation. We have clinically proven the superiority of our technology with sublingual aspirin, de-risking the platform, and we have demonstrated our ability to execute commercially with Buzz Bomb Caffeine Company’s successful launch of BUZZ BOMB™.”

Higginson continued, “Looking ahead, investors can see a clear line of sight to a series of major, value-driving catalysts. The most significant is our targeted NDA submission for sublingual aspirin in the first half of 2026, which aims to disrupt a multi-billion-dollar market. This will be followed by the initiation of clinical studies for our sublingual ED and other programs, our entry points into some of the largest pharmaceutical markets in the world. Our ability to scale commercially is already being validated, as demonstrated by Buzz Bomb Caffeine Company’s second production order of two million servings of BUZZ BOMB™ to meet growing demand. We believe the accomplishments of this quarter have set the stage for a transformative period of growth, and the market has yet to fully recognize the value of the catalysts that lie directly ahead.”

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.

Contact

Brett Maas
Hayden IR: (646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR: (646)-755-7412
james@haydenir.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

Meeting scheduled to reconvene December 19, 2025, at 1:00 p.m. ET

ORLANDO, FLORIDA / ACCESS Newswire / December 4, 2025 / Unusual Machines, Inc. (NYSE American:UMAC), a leading provider of NDAA-compliant drone components, today announced that its Annual Meeting of Stockholders, which convened on December 1, 2025, has been adjourned until December 19, 2025, at 1:00 p.m. ET. to solicit additional proxies to achieve a quorum and for its proposal to approve the election of five directors for a one-year term expiring at the next Annual Meeting of Stockholders. The adjourned meeting will be a completely “virtual” meeting of the stockholders, and stockholders will be able to listen and participate in the virtual meeting as well as vote during the live webcast of the meeting by visiting www.virtualshareholdermeeting.com/UMAC2025 and entering the control ID and Request ID number printed on the form of proxy or voting instruction form.

The Board of Directors believes approval of the proposal is in the best interests of Unusual Machines, Inc. and its stockholders. The proposal is described in more detail in Unusual Machines, Inc.’s proxy statement dated October 20, 2025, furnished to stockholders in connection with the Annual Meeting filed under the Company’s EDGAR profiles. It can also be found on the Company’s website at https://www.unusualmachines.com/financials/sec-filings/#

At the time of the meeting, there was no quorum, and insufficient votes were cast to approve the proposal. Unusual Machines encourages any stockholder who has not yet voted their shares on the proposal or is uncertain whether their shares have been voted on the proposal to contact their broker or bank. The record date of the meeting shall remain October 6, 2025. Accordingly, the Board of Directors and management request that stockholders as of the record date, October 6, 2025, please vote their proxies as soon as possible, but no later than December 18, 2025, at 11:59 p.m. (Eastern Time). Stockholders who have previously submitted their proxy or otherwise voted for the proposal and who do not want to change their vote need not take any action.

How do I vote?

If you are a stockholder of record, you may vote*:

1. By Internet. The website address for Internet voting is on your proxy card.

2. By phone. Call 1-800-690-6903 and follow the instructions on your proxy card.

3. By mail. Mark, date, sign, and mail promptly the enclosed proxy card (a postage-paid envelope is provided for mailing in the United States).

4. In person: You may vote in person by attending the virtual Annual Meeting.

* If you vote by Internet or phone, please DO NOT mail your proxy card.

If your shares are held in street name, you may vote:

1. By Internet. The website address for Internet voting is on your voting instruction form provided by your bank, broker, or similar organization.

2. By mail. Mark, date, sign, and mail promptly the enclosed voting instruction form provided by your bank or broker.

3. In person: You may vote in person by attending the virtual Annual Meeting.

If you are a beneficial owner, you must follow the voting procedures of your nominee included with your proxy materials. If your shares are held by a nominee and you intend to vote at the Annual Meeting, please be prepared to demonstrate proof of your beneficial ownership as of the record date (such as your most recent account statement as of the record date, a copy of the voting instruction form provided by your broker, bank, trustee or nominee, or other similar evidence of ownership) and a legal proxy from your nominee authorizing you to vote your shares.

What constitutes a Quorum?

To carry on the business of the Annual Meeting, we must have a quorum. A quorum is present when one-third of the voting power of the outstanding shares of all classes or series of stock entitled to vote, as of the record date, are represented in person or by proxy. Shares owned by Unusual Machines are not considered outstanding or present at the Annual Meeting. Broker non-votes (because there are routine matters presented at this Annual Meeting) and abstentions are counted as present for the purpose of determining the existence of a quorum.

Stockholder Questions

If you have any questions or require any assistance in voting your shares, please call Innisfree M&A Incorporated at 877-800-5186.

About Unusual Machines

Unusual Machines manufactures and sells drone components and drones across a diversified brand portfolio, which includes Fat Shark, the leader in FPV (first-person view) ultra-low latency video goggles for drone pilots. The Company also retails small, acrobatic FPV drones and equipment directly to consumers through the curated Rotor Riot ecommerce store. With a changing regulatory environment, Unusual Machines seeks to be a dominant Tier-1 parts supplier to the fast-growing multi-billion-dollar U.S. drone industry. According to Fact.MR, the global drone accessories market is currently valued at $17.5 billion and is set to top $115 billion by 2032. For more information, please visit www.unusualmachines.com.

Investor Contact:

CS Investor Relations
investors@unusualmachines.com

SOURCE: Unusual Machines, Inc.

View the original press release on ACCESS Newswire

Matches to be available free to fans through a new, dedicated LOVB content hub on the Victory+ platform

LOS ANGELES, CALIFORNIA / ACCESS Newswire / December 4, 2025 / League One Volleyball (LOVB), the largest brand in youth volleyball and the first-of-its-kind youth-to-pro volleyball league in the United States, today announced a multi-year media rights partnership with Victory+, significantly expanding access to LOVB’s match play and off-court content.

“This partnership marks a massive step forward for LOVB and for professional volleyball in the U.S. Together with Victory+, we’re making the sport easier to watch, easier to love, and impossible to ignore,” said Raquel Braun, Chief Media Officer for LOVB. “The platform’s national reach and best-in-class technology will help us elevate our athletes and give fans a centralized home for the entire LOVB experience.”

As part of the agreement, Victory+ will carry more than 20 regular-season matches each year, along with select postseason matches, including two postseason events in the 2026 season. 

United in a shared mission to redefine the modern volleyball broadcast, LOVB and Victory+ will collaborate to create a viewing experience as dynamic as the game itself. By blending creator-driven content, experimental formats, and deep behind-the-scenes storytelling, the content hub will offer an immersive ecosystem that breaks down the barrier between athlete and audience.

“We are proud to partner with League One Volleyball to elevate these exceptional athletes and build something truly transformative in American sports,” said Katie Boes, Chief Content Officer, Victory+. “Adding LOVB to a portfolio that includes the NWSL and WNFC cements Victory+ as a destination for women’s sports fandom and underscores our commitment to equity through unrestricted access.”

All Victory+ LOVB matches will be available free to fans through a new, dedicated LOVB content hub on Victory+. The hub will feature:

• Live and on-demand LOVB matches

• Original storytelling and behind-the-scenes series

• Dedicated sections for each LOVB pro team, showcasing players, culture, and local community ties

• Expanded coverage of the LOVB ecosystem, from youth clubs to the professional stage

“By centralizing LOVB’s content experience, fans will have seamless access to the personalities, stories, and moments that define the sport, which we believe will help catapult LOVB athletes into national spotlights and household-name status,” said Braun. 

LOVB is redefining volleyball in the U.S. through its unprecedented youth-to-pro model, deeply connected community clubs, and the largest pipeline of elite volleyball talent in the country. With this multi-year partnership, LOVB continues to scale momentum, visibility, and commercial investment behind one of America’s fastest-growing sports.

For more information about LOVB Pro as it heads into its second season, please visit: www.LOVB.com

About LOVB
Founded in 2020, LOVB’s mission is to reimagine the future of volleyball. With a unique community up approach, LOVB is one holistic ecosystem – from club to pro. The largest community of youth clubs in the country, LOVB launched the first serve of its pro league in January 2025, featuring some of the very best players in the world including American silver medalists and players from the last Olympics. For more information on LOVB as it embarks on its second season, its clubs, and its professional teams in Atlanta, Austin, Houston, Madison, Omaha, Salt Lake, and soon to be Los Angeles, please visit www.lovb.com or on social channels like Instagram.

About Victory+
Victory+ is a free, sports streaming platform that puts fans first, giving them direct access to the teams and leagues they love. It features regional broadcasts of teams including the Dallas Stars, Anaheim Ducks, and Texas Rangers, along with national coverage of highly popular leagues such as the WHL and NWSL. Victory+ is also the home to a library of on-demand, premium sports-based, outdoors, and extreme sports content.

Contact Information

Madeleine Moench
madeleine@newswire.com

Jeremy Mason
Chief Brand Officer
media@aparentmedia.com

SOURCE: A Parent Media Co. Inc.

Related Images

View the original press release on ACCESS Newswire

Lightweight, Elastic Enforcement Layer Delivers Full-Fidelity Visibility and Reputation-Based Blocking for Cloud Workloads

PLANO, TEXAS / ACCESS Newswire / December 10, 2025 / Intrusion Inc. (NASDAQ:INTZ) (“Intrusion” or the “Company”), a leader in cyberattack prevention solutions, announced today the general availability of Shield Stratus, a cloud-native packet filtering solution that inspects every connection and blocks known threats immediately without the complexity or re-architecture required by traditional firewalls.

Shield Stratus integrates seamlessly with Amazon Web Services (AWS) Gateway Load Balancer to deliver full-fidelity traffic inspection and reputation-based enforcement at the VPC layer. Unlike legacy virtual firewalls or flow sampling tools, Shield Stratus sees 100% of network traffic and blocks malicious actors at first contact, preventing data exfiltration and C2 communication before damage occurs.

“Cloud security has been too polite for too long,” said Tony Scott, CEO of Intrusion. “Traditional firewalls don’t function in the way the cloud requires. Shield Stratus is built for cloud speed and scale without compromising visibility and security. This is the new age of autonomous enforcement for the cloud.”

The Shield Stratus Advantage

Shield Stratus addresses critical gaps in cloud security by delivering:

Full-Fidelity Inspection

Inspects every packet, not sampled flows, eliminating blind spots

Reputation-Based Blocking

Leverages Intrusion’s threat intelligence to block malicious, unknown, and untrustworthy connections based on calculated risk

Elastic, Cloud-Native Architecture

Deploys in minutes via AWS CloudFormation templates with zero ongoing maintenance

Observe and Protect Modes

Enables teams to start with full visibility before enforcing blocking policies

Unified Management

Centralized policy control and AI-powered insights through Command Hub across all Shield products

Built for Modern Cloud Teams

Shield Stratus is designed for security teams, MSSPs, and DevOps professionals who need egress filtering and threat enforcement without the operational overhead of traditional NGFWs. The solution supports hub-and-spoke architectures and multi-VPC deployments, all from a single Command Hub console.

Part of the Shield Ecosystem

Shield Stratus joins Intrusion’s comprehensive Shield platform, which includes Shield Gateway (full-featured virtual firewall/NAT instance), Shield OnPrem (hardware-based edge enforcement), and Shield Endpoint (remote worker protection), all managed through the centralized Command Hub with unified threat intelligence and AI-driven insights.

About Intrusion Inc.

Intrusion Inc. is a cybersecurity company based in Plano, Texas, specializing in advanced threat intelligence. At the core of its capabilities is TraceCop, a proprietary database that catalogs the historical behavior, associations, and reputational risk of IPv4 and IPv6 addresses, domain names, and hostnames. Built on years of gathering global internet intelligence and supporting government entities, this data forms the backbone of Intrusion’s commercial solutions.

Its most recent solution is Intrusion Shield – a next-generation network security platform designed to detect and prevent threats in real time. In observe mode, Shield delivers analytical insights powered by Intrusion’s exclusive data, helping organizations identify unseen patterns and previously unknown risks. In protect mode, it monitors traffic flow and automatically blocks known malicious and unknown connections from entering or exiting the network – providing a powerful defense against Zero-Day threats and ransomware. By integrating Shield into a network, organizations can elevate their overall security posture and enhance the performance of their broader cybersecurity architecture.

IR Contact:

Alpha IR Group
Mike Cummings or Josh Carroll
INTZ@alpha-ir.com

SOURCE: Intrusion Inc.

View the original press release on ACCESS Newswire